Dabigatran Etexilate Capsules Recalled Over Impurity Test Failure
Ascend Laboratories is recalling 1,753 cartons of dabigatran etexilate capsules (lot 25141707) due to out-of-specification results in impurity testing during 12-month stability studies.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall, which by definition is not likely to cause adverse health consequences. No illnesses or injuries have been reported, and the issue involves an out-of-specification result in impurity testing rather than confirmed contamination or harm.
Plain-English summary
Ascend Laboratories, LLC is recalling 1,753 cartons of Dabigatran Etexilate Capsules, 110 mg, 60-count cartons (NDC 0904-7254-68), lot 25141707, with an expiration date of April 30, 2027. The product was distributed nationwide across the United States.
The recall was initiated due to an out-of-specification (OOS) result observed during related substance test analysis. Specifically, the OOS result involved Impurity II, Impurity III, and Total Impurity testing conducted as part of a 12-month long-term stability study.
The affected product is a prescription anticoagulant medication. No illnesses or injuries have been reported in connection with this recall.
Consumers or healthcare providers in possession of the recalled lot should not use the product. Ascend Laboratories is a division of Major Pharmaceuticals, which is handling the recall. Healthcare providers should contact their pharmacy or distributor to arrange for return or replacement of the affected medication.
The recalled product
- Product
- DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE)
- Brand
- DABIGATRAN ETEXILATE
- Manufacturer
- Ascend Laboratories, LLC
- Category
- Drug — Prescription Capsule
- Affected units
- 1,753
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 25141707
- Exp 4/30/2027.
UPCs (2)
- 0309047253043
- 0309047255108
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Ascend Laboratories, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · DABIGATRAN ETEXILATE
- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Over Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateDrug Recall: Dabigatran Etexilate Capsules 150 mg by Ascend Laboratories
FDA (Drugs) · 2026-07-29
- HighPrescription drug Dabigatran Etexilate recalled for elevated nitrosamine impurity
FDA (Drugs) · 2024-12-18
Same manufacturer · Ascend Laboratories, LLC
See all →- ModerateFDA Recalls Amlodipine and Olmesartan Tablets Over Failed Dissolution Test
FDA (Drugs) · 2026-07-29
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10